Skip to main content
APVO logo

APVO · Aptevo Therapeutics Inc.

Track APVO — free
$0.41 0.00 (-0.34%)
Market Cap
$1.43M
Shares
3.46M
Volume · Nov 20 88.68K Avg daily vol (3M) 130.94K

Price & Indicators

 

Key stats

Close
$0.41
Thu 19 Nov
Open
$0.45
Thu 19 Nov
Average volume, 30 days
122K
shares a session
Short interest
71K
2.1% of shares · 1.9 days to cover
Day range
$0.38$0.46
Open $0.45 Close $0.41
52-week closing range
$0.41$25.02
Close $0.41 98.3% under the high
Short volume, last session
57%
Latest filing
10-Q · Nov 16
Price history
Mar 2020 to Nov 2026

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $8.3 million falls short of funding needs

Aptevo held $8.3 million of cash as of September 30, 2026, versus $19.1 million of operating cash use for the nine months ended September 30, 2026, and said existing resources will not fund operations for at least one year.

Net loss $6.55M Diluted EPS -$5.19
Read from the MD&A section
4 source passages
We had cash and cash equivalents of $8.3 million and an accumulated deficit of $297.6 million as of September 30, 2026. For the nine months ended September 30, 2026, net cash used in our operating activities was $19.1 million. Our existing cash resources are not expected to be sufficient to fund operations for at least one year from the date the financial statements are issued. Manufacturing progress moves the next-generation trispecifics closer to human testing. This expands Aptevo's opportunities into solid tumors beyond AML. Open the document at this passage
Nov 16
Current report 8-K
Mipletamig shows 79% remission rate in TP53-mutated AML

Aptevo reported third-quarter 2026 results, with mipletamig achieving a 79% remission rate in high-risk TP53-mutated AML. Cash and cash equivalents were $8.3 million as of September 30, 2026, and the third-quarter net loss was $6.5 million.

Financial results
3 source passages
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Cash and cash equivalents totaled $8.3 million as of September 30, 2026 Net loss for the third quarter of 2026 was $6.5 million Open the document at this passage
Nov 12
Proxy statement PRE 14A
Stockholders to vote on warrant issuance and reverse split

Aptevo Therapeutics Inc. will ask stockholders on December 14, 2026 to authorize warrant-related issuance equal to 20% or more of outstanding Common Stock or voting power, approve a 1-for-3 to 1-for-10 reverse split, and approve its Sixth Amended and Restated 2018 Stock Incentive Plan.

Read from the first part of this long document
4 source passages
The meeting will be held on December 14, 2026, at 10 a.m. Pacific Time. To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), and/or securities convertible into or exercisable for Common Stock, that equals 20% or more of the Common Stock or the voting power outstanding before the issuance To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the outstanding Common Stock, at a ratio in the range of 1-for-3 to 1-for-10 To approve the Aptevo Therapeutics Inc. Sixth Amended and Restated 2018 Stock Incentive Plan Open the document at this passage
Nov 12
Current report 8-K Events of Nov 11
Warrant Reload Could Yield $15.0 Million in Additional Proceeds

Aptevo Therapeutics Inc. received approximately $3.0 million from holders exercising existing warrants covering 2,777,778 shares, then issued new warrants for 13,888,890 shares at $1.08 per share, potentially generating approximately $15.0 million.

Entered into a material agreement, Unregistered sale of equity, Other events Read from the first part of this long document
3 source passages
On November 11, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Warrant Inducement and Reload Letters (the “Inducement Letters”) with certain holders (the “Holders”) of the Company’s inducement common stock purchase warrants and PIPE common stock purchase warrants, each issued on August 13, 2026 (the “Existing Warrants”), pursuant to which the Holders agreed to exercise in full for cash the Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock (“Common Stock”) of the Company (the “Existing Warrant Shares”) at a reduced exercise price of $1.08 per share (the “Warrant Exercise”). In consideration of the Holders’ agreement to exercise the Existing Warrants in accordance with the Inducement Letters, the Company issued new unregistered common stock purchase warrants (the “Inducement Warrants”) to purchase up to an aggregate of 13,888,890 shares of Common Stock (the “Inducement Warrant Shares”), representing 500% of the number of Existing Warrant Shares issued pursuant to the Warrant Exercise, at an exercise price of $1.08 per share (the “Warrant Reload” and, together with the Warrant Exercise, the “Transaction”). The Company received aggregate gross proceeds of approximately $3.0 million from the Warrant Exercise, before deducting placement agent fees and other offering expenses payable by the Company. If the Inducement Warrants are exercised in full for cash, the Company would receive additional gross proceeds of approximately $15.0 million. Open the document at this passage
Nov 9
Current report 8-K
Preclinical immunotherapies showed tumor-cell killing under immune suppression

Aptevo Therapeutics Inc. reported preclinical results from its November 7, 2026 SITC presentation: APVO451 and APVO452 activated T cells and killed cancer cells under immunosuppressive conditions, while APVO711 combined CD40 activation with PD-L1 blockade.

Other events
3 source passages
Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. In preclinical studies, APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation under immunosuppressive conditions. Preclinical findings with APVO711 demonstrated the ability to combine CD40 activation with PD-L1 checkpoint blockade, addressing two mechanisms involved in regulating the immune response. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$25.41M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 403,249.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+700.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.1%
Latest settlement · 1.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −89%
below
Price vs 50-day avg −72%
below
RSI (14) 9
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −74%
trailing
6-month return −92%
trailing
YTD return −96%
this year
Relative strength −86%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.06% of shares out · ▼ -26.2% MoM · 1.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
11 holders — mid 3-yr range
Squeeze score 33
low risk · 0–100
Fundamentals
Strong
Revenue growth −75%
Y/Y
EPS growth +100%
Y/Y
Free cash flow $-25.6M
Buyback $8.0M
remaining
Balance sheet $21.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −98%
past year
ATR 28.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−89% Bearish
Price vs 50-day avg
−72% Bearish
RSI (14)
9 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+22% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.06% of shares out · ▼ -26.2% MoM · 1.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $25
vs 200-day avg -89% vs 50-day avg -72%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
evaluable frontline patients 47 October 2026 —
evaluable TP53-mutated patients 14 September 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
APVO
Aptevo Therapeutics Inc.
this stock
$1.43M -95.6% -74.7% — 2.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
9.8%
Net QoQ
+288.9K sh
Top holder
SABBY MANAGEMENT, LLC
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Falling
Shares short
71.3K
Days to cover
1.9d
Change
-25.3K sh
View
Short Volume
Short vol %
57%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
2.1K
Value
$2.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
60.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$3.1M
Net income (FY)
$-26.0M
EPS diluted
$-87.27
View
Buybacks
Remaining
$8.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
37

Aptevo reported third-quarter 2026 results, with mipletamig achieving a 79% remission rate in high-risk TP53-mutated AML. Cash and cash equivalents were $8.3 million as of September 30, 2026, and the third-quarter net loss was $6.5 million.

View
Exempt Offerings
Offering
$3.5M
Filed
Aug 26, 2026
View
Earnings & Events
Investor Relations
Latest news
Aptevo Provides 3Q26 Business Upd…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
APVO -37.3% -74.3% -92.1% -69.1% -95.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -31.9% -68.0% -86.5% -63.8% -100.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$8.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1671584 CUSIP 03835L702 13F (30d) 14 filings 12 filers Visit website Investor relations